Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multicenter, Single Arm Study of RBN-2397 in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (SCCL)

NCT05127590 is registered in ClinicalTrials.gov with Ribon Therapeutics, Inc. as lead sponsor.

NCT NCT05127590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05127590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multicenter, Single Arm Study of RBN-2397 in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (SCCL)
Lead sponsor
Ribon Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 15, 2022
Completion date
December 31, 2023
Enrollment
50 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced squamous non-small cell lung carcinoma